KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Takeda Pharmaceutical (TAK) Cost of Revenue (2017 - 2025)

Historic Cost of Revenue for Takeda Pharmaceutical (TAK) over the last 9 years, with Q4 2025 value amounting to $2.6 billion.

  • Takeda Pharmaceutical's Cost of Revenue rose 331.46% to $2.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $16.0 billion, marking a year-over-year increase of 242.68%. This contributed to the annual value of $10.4 billion for FY2025, which is 486.34% up from last year.
  • Per Takeda Pharmaceutical's latest filing, its Cost of Revenue stood at $2.6 billion for Q4 2025, which was up 331.46% from $8.1 billion recorded in Q3 2025.
  • In the past 5 years, Takeda Pharmaceutical's Cost of Revenue registered a high of $8.1 billion during Q3 2025, and its lowest value of $2.2 billion during Q2 2021.
  • For the 5-year period, Takeda Pharmaceutical's Cost of Revenue averaged around $3.0 billion, with its median value being $2.5 billion (2022).
  • As far as peak fluctuations go, Takeda Pharmaceutical's Cost of Revenue tumbled by 1172.5% in 2022, and later soared by 20579.29% in 2024.
  • Over the past 5 years, Takeda Pharmaceutical's Cost of Revenue (Quarter) stood at $2.5 billion in 2021, then decreased by 3.94% to $2.4 billion in 2022, then rose by 8.67% to $2.6 billion in 2023, then dropped by 2.39% to $2.5 billion in 2024, then grew by 3.31% to $2.6 billion in 2025.
  • Its Cost of Revenue was $2.6 billion in Q4 2025, compared to $8.1 billion in Q3 2025 and $2.7 billion in Q2 2025.